GLP1 (SEMA) 10MG
GLP1 is a synthetic peptide that acts as a long-acting glucagon-like peptide-1 receptor agonist. In laboratory research, it is utilized to investigate the regulation of glycemic levels and the physiological pathways involved in appetite suppression and metabolic homeostasis. For research use only.
- GLP-1 Receptor Agonism: Investigated for its ability to mimic the endogenous GLP-1 hormone to stimulate glucose-dependent insulin secretion and inhibit glucagon release.
- Metabolic and Satiety Research: Studied for its role in slowing gastric emptying and interacting with hypothalamic receptors to modulate hunger and energy intake in animal models.
| Aspect | Semaglutide (e.g., Ozempic/Wegovy) | Tirzepatide (e.g., Mounjaro/Zepbound) | Retatrutide (investigational, “Triple G”) |
|---|---|---|---|
| Drug Class | GLP-1 receptor agonist | Dual GLP-1 / GIP receptor agonist | Triple GLP-1 / GIP / glucagon receptor agonist |
| Primary Mechanism | Mimics GLP-1: glucose-dependent insulin release, suppresses glucagon, slows gastric emptying, reduces appetite via brain signaling | Adds GIP agonism: enhanced insulin secretion, better appetite control & metabolic synergy with GLP-1 | Adds glucagon agonism: increases energy expenditure (fat burning), further appetite suppression & liver fat reduction |
| Administration | Subcutaneous injection (weekly) or oral (daily) | Subcutaneous injection (weekly) | Subcutaneous injection (weekly) |
| FDA Status (2026) | Approved for T2D, obesity, CV risk reduction | Approved for T2D & obesity | Investigational (Phase 3 ongoing; not approved) |
| Average Weight Loss (obesity trials, ~68-72 weeks) | ~14-20% (e.g., 14.9% in STEP 1; up to ~20% with higher doses) | ~18-22% (e.g., up to 20.9-21% in SURMOUNT trials; often superior to semaglutide) | ~24-29% (e.g., 24.2% at 48 weeks Phase 2; up to 28.7% at 68 weeks in Phase 3 topline) |
| Key Benefits | Strong glycemic control, CV protection, heart failure improvement, kidney benefits | Superior weight/fat loss, better glucose control, sleep apnea & knee OA improvements | Highest reported weight loss, potent liver fat reduction (up to 82%), potential thermogenic effects |
| Common Side Effects | Nausea, vomiting, diarrhea (dose-related, often transient); injection-site reactions | Similar GI effects (nausea/vomiting/diarrhea); generally well-tolerated but dose escalation needed | Similar GI profile (nausea, vomiting, diarrhea); comparable to other incretins |
| Serious Risks | Rare: pancreatitis, gallbladder issues, thyroid C-cell tumors (rodent data, low human risk) | Similar rare risks; monitor for GI & gallbladder | Similar profile; long-term data still emerging |
| Typical Use Context | Established first-line for T2D/obesity with CV benefit | Preferred for maximal weight loss in obesity | Emerging for extreme weight loss & metabolic research |
ergonjobssite@gmail.com –
recieved the product within a few days after ordering, cant complain, seems legit!
Amely –
The best on the market, arrived super fast, had a good chat with costumer service, 100% recommand!
Sarah M. –
PenformTM Semaglutide works just like Ozempic—down 28 lbs in 3 months, same appetite control. Fraction of the price! Arrived in 3 days, super discreet box. Love it.
Mike R. –
Switched from expensive Ozempic to PenformTM Semaglutide. Identical results—35 lbs gone. Huge savings. Ordered Tuesday, delivered Thursday—fast and unmarked. Great!
Emily T. –
Feels exactly like Ozempic. Lost 22 lbs in 2 months, no difference. Way cheaper. Came in 4 days, discreet packaging. Solid choice.
James –
Top Top
Macarena –
Best vendor!
Need More –
Versatile quality